| 
             Hodgkin  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Non-Hodgkin  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Medulloblastoma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Low-Grade Glioma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             DIPG / High-Grade Glioma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Ependymoma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Neurofibromatosis  | 
        |
| Sarcoma / MPNST New Diagnosis | Sarcoma / MPNST Relapse / Refractory | 
| NF2 | Plexiform Neurofibroma | 
| OPG / Low-Grade Glioma | Other Neurofibromatosis | 
| 
             Other Brain and Spinal Tumors  | 
        |
| ATRT | Craniopharyngioma | 
| Germ Cell Tumor | Choroid Plexus Tumor | 
| All Other | |
| 
             Osteosarcoma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Ewing Sarcoma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Rhabdomyosarcoma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Desmoid Tumors  | 
        |
| New Diagnosis | Relapse / Refractory | 
| New Diagnosis | Relapse / Refractory | 
| 
             Liver  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Kidney  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Retinoblastoma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Neurofibromatosis  | 
        |
| Sarcoma / MPNST New Diagnosis | Sarcoma / MPNST Relapse / Refractory | 
| NF2 | Plexiform Neurofibroma | 
| OPG / Low-Grade Glioma | Other Neurofibromatosis | 
| 
             Melanoma  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             Germ Cell Tumor  | 
        |
| New Diagnosis | Relapse / Refractory | 
| 
             All Other Solid Tumors  | 
        |
| All Other | |
To learn more about available clinical trials, contact us at cancer@cchmc.org or 513-636-2799.
The Cancer and Blood Diseases Institute closely integrates patient care and research to advance knowledge and improve outcomes for our patients. We are known for offering the most advanced therapies − some of which were originally developed here by nationally recognized specialists.
The Oncology Division is a national referral center for specialized leading-edge care of children and young adults with cancer and leukemia and for multidisciplinary long-term follow-up of cancer survivors.
Subscribe to our bi-monthly newsletter for a full list of adolescent and young adult clinical trials.